Document Type
Article
Publication Date
5-2024
Publisher
Elsevier
Source Publication
mBio
Source ISSN
2150-7511
Original Item ID
DOI: 10.1128/mbio.00519-24
Abstract
Today, more than 90% of people with cystic fibrosis (pwCF) are eligible for the highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy called elexacaftor/tezacaftor/ivacaftor (ETI) and its use is widespread. Given the drastic respiratory symptom improvement experienced by many post-ETI, clinical studies are already underway to reduce the number of respiratory therapies, including antibiotic regimens, that pwCF historically relied on to combat lung disease progression. Early studies suggest that bacterial burden in the lungs is reduced post-ETI, yet it is unknown how chronic Pseudomonas aeruginosa populations are impacted by ETI. We found that pwCF remain infected throughout their upper and lower respiratory tract with their same strain of P. aeruginosa post-ETI, and these strains continue to evolve in response to the newly CFTR-corrected airway. Our work underscores the continued importance of CF airway microbiology in the new era of highly effective CFTR modulator therapy.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Armbruster, Catherine R.; Hilliam, Yasmin K.; Zemke, Anna C.; Atteih, Samar; Marshall, Christopher; Moore, John; Koirala, Junu; Krainz, Leah; Gaston, Jordan R.; Lee, Stella E.; Cooper, Vaughn S.; and Bomberger, Jennifer M., "Persistence and Evolution of Pseudomonas aeruginosa Following Initiation of Highly Effective Modulator Therapy in Cystic Fibrosis" (2024). Biological Sciences Faculty Research and Publications. 959.
https://epublications.marquette.edu/bio_fac/959
Comments
Published version. mBio, Vol. 15, No. 5 (May 2024). DOI. © 2024 American Society for Microbiology. Used with permission.